Features | Partner Sites | Information | LinkXpress
Sign In
BioConferenceLive
European Federation of Biotechnology
JIB

Virtual Screening Identifies New Low Molecular Weight Anticancer Drug Candidates

By BiotechDaily International staff writers
Posted on 21 Feb 2013
Computer modeling and high throughput molecular screening were used to identify low molecular weight compounds capable of blocking the activity of procancerous signaling molecules called G-protein mediated Rho guanine nucleotide exchange factors (GEFs).

GEFs have been implicated in several human diseases including cancer, but finding suitable drugs to block their activity has proven difficult due to a lack of distinctive formational features in the three-dimensional structure of these molecules. Investigators at Cincinnati Children's Hospital Medical Center (OH, USA) have approached this problem from a new direction.

They reported in the February 4, 2013, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) that they had virtually screened chemicals that fit into a surface groove of the DH-PH domain of LARG (leukemia-associated Rho guanine nucleotide exchange factor), a G-protein-regulated Rho GEF involved in RhoA activation, and had followed up the virtual tests with validations in biochemical assays. This methodology allowed them to identify a class of chemical inhibitors represented by Y16 that was active in specifically inhibiting LARG binding to RhoA.

RhoA (Ras homolog gene family, member A) is a small GTPase protein known to regulate the actin cytoskeleton in the formation of stress fibers. This protein is essential for the signaling function of the Rho GTPase complex. Previous studies have shown that in breast cancer increased RhoA activity stimulated cancer cell invasiveness and spreading, while RhoA deficiency suppressed cancer growth and progression. In addition to its role in breast cancer, imbalance in Rho GTPase activity has been implicated in other human diseases, including various cancers and neurological disorders.

The suppressive effect of Y16 was significantly amplified by using the compound together with Rhosin/G04, a drug previously shown to target RhoA. The combination of Y16 and Rhosin/G04 did not interfere with other cellular signaling functions.

"We are using the findings from this study to refine our compounds and test them on mouse models of acute myeloid leukemia and certain metastatic tumors—especially breast cancer, where the target pathway of this lead inhibitor is hyperactive," said senior author Dr. Yi Zheng, professor of pediatrics at Cincinnati Children's Hospital Medical Center.

Related Links:
Cincinnati Children's Hospital Medical Center


comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: A microscope image of a neuron with inclusion (stained orange) caused by Huntington\'s disease (Photo courtesy of Wikimedia Commons).

Molecular Interactions Identified That Block Protein Transfer into Mitochondria of Huntington's Disease Neurons

Researchers have identified a protein complex that interacts with the mutated form of huntingtin protein to impair transport of proteins into the mitochondria of brain cells, which leads to their malfunction... Read more

Drug Discovery

view channel
Image: A mouse mammary gland missing the tumor-suppressor p53 shows expression of ARF (green), now known for a backup role in protecting cells from becoming cancerous. If both p53 and ARF are mutated, the tumors that form are aggressive and may benefit from treatment with anti-inflammatory drugs called JAK inhibitors, currently prescribed for rheumatoid arthritis (Photo courtesy of Raleigh Kladney).

Anti-Inflammatory Drugs May Treat Some Aggressive Rumors

New research raises the possibility that some cancer patients with aggressive tumors may benefit from a class of anti-inflammatory drugs used to treat rheumatoid arthritis. By studying triple-negative... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.